Broadwood Partners, L.P.'s Form 4 filing
Lineage Cell Therapeutics, Inc.LCTX · filed Mar 25, 2022
- Accession no.
- 0000919574-22-002418
- Filed
- Mar 25, 2022, 5:56 PM ET
- Trade date
- Mar 23-25, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions. Open-market purchases total $1.32M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Broadwood Partners, L.P.CIK 0001278386 | Director, 10% Owner |
| Bradsher Neal CCIK 0001278388 | Director, 10% Owner |
| Broadwood Capital IncCIK 0001278387 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 23, 2022 | Common Shares | PPurchaseAcquired | +260,106 | $1.37F2 | +$355,304.8 | 34,265,485 | Direct | |
| Mar 23, 2022 | Common Shares | PPurchaseAcquired | 0 | $0.00 | $0 | 34,265,485 | Indirect | |
| Mar 24, 2022 | Common Shares | PPurchaseAcquired | +200,000 | $1.42F3 | +$284,340 | 34,465,485 | Direct | |
| Mar 24, 2022 | Common Shares | PPurchaseAcquired | 0 | $0.00 | $0 | 34,465,485 | Indirect | |
| Mar 25, 2022 | Common Shares | PPurchaseAcquired | +470,000 | $1.44F4 | +$678,022 | 34,935,485 | Direct | |
| Mar 25, 2022 | Common Shares | PPurchaseAcquired | 0 | $0.00 | $0 | 34,935,485 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This constitutes the weighted average purchase price. The prices range from $1.33 to $1.38. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the "SEC Staff"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
This constitutes the weighted average purchase price. The prices range from $1.37 to $1.44. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
This constitutes the weighted average purchase price. The prices range from $1.36 to $1.50. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.